clinical trial · NCT03701399
Troriluzole in Adult Participants With Spinocerebellar Ataxia
Biohaven Pharmaceuticals, Inc.·phase3·active not recruiting·n = 299
Spinocerebellar AtaxiasSpinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 6Spinocerebellar Ataxia Type 7Spinocerebellar Ataxia Type 8Spinocerebellar Ataxia Type 10troriluzolePlacebo
brief summary
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
started
Mar 8, 2019
primary completion
Feb 18, 2022
completion
Jun 1, 2026
last updated
Nov 4, 2025
official title
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol